A lab in Oklahoma is studying genes for combinations that predict breast cancer risk. A look into the 100 genes gathered from each woman -- via mouthwash -- allows researchers to categorize women with standard, moderate, or high risks of developing the disease.

The study begins with a lengthy questionnaire about medical history and leads to the collection of a DNA sample. Women simply rinse their mouths with a standard mouthwash and wait for results.

Geneticist Dr. Kara Casas says she hopes that regardless of results, women will choose a healthy lifestyle with a diet low in fat and alcohol consumption and with lots of exercise too. But those in the moderate and high-risk groupings will be advised to make other lifestyle changes to help decrease their chances of getting breast cancer. They may be asked to regulate estrogen levels, for example, and to report regularly for mammograms at an earlier age.

Casas says all women have some risk of developing breast cancer. But knowing what these risks are can help them better protect themselves -- which makes tests like this so important.

A total of 12,000 samples will collected for an FDA trial. For more information about this study in mouthwash, call 903-510-1173.

A type of Non-Hodgkin's lymphoma (NHL) called mantle cell lymphoma accounts for about five to ten percent of all lymphomas. According to an article recently published in the Journal of Clinical Oncology, Velcade (bortezobib) is an effective treatment option for patients with mantle cell lymphoma that has stopped responding to prior treatments.

Velcade is an agent known as a proteasome inhibitor. Proteasome inhibitors are drugs that block the action of proteasomes, proteins found in virtually all cells that regulate several aspects of cellular activity. By blocking the activity of proteasomes it can lead to the death of cancer cells. Bortezobib is the first therapeutic proteasome inhibitor to be approved for use in the United States.

Researchers conducted a clinical trial to evaluate Velcade in the treatment of fifteen patients with mantle cell lymphoma that has recurred or progressed following prior therapies. Anticancer responses occurred in 33 percent of patients and after over 13 months follow up, over half the patients were still surviving.